Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation

SAN DIEGO, June 22, 2011 /PRNewswire/ — Cardium Therapeutics
(NYSE Amex:
CXM) today announced the selection of the Cedars-Sinai Medical
Center Nuclear Cardiology Core Laboratory (Cedars-Sinai Core
Laboratory), Los Angeles, California, to serve as the central core
lab for the Company’s Generx ASPIRE clinical study.
 Cedars-Sinai Core Laboratory will be responsible for the
consolidation and analysis of SPECT (single-photon emission
computed tomography) myocardial imaging data from the Russian
medical centers participating in the Generx® Phase 3 ASPIRE
registration study that recently received clearance for initiation
from the Russian Ministry of Health and Social Development.
 SPECT is a common imaging technique that is used throughout
the world to quantitatively assess myocardial ischemia in patients
with coronary artery disease.  The ASPIRE study’s
primary endpoint will be improvement in perfusion (blood flow)
defect size as measured by SPECT imaging.

(Photo:  http://photos.prnewswire.com/prnh/20110622/LA24240)

(Logo:  http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

Cedars-Sinai Medical Center Nuclear Cardiology Core Laboratory
is considered one of the world’s leading core laboratories
for SPECT imaging.  It has operated as an independent core
laboratory for over 20 years and has participated in numerous
multi-center clinical trials, including the recent COURAGE
(Clinical Outcomes Utilizing Revascularization and Aggressive Drug
Evaluation) clinical study enrolling over 3,200 patients at over 60
clinical study sites.  The scope of work performed by the
Cedars-Sinai Core Laboratory includes imaging protocol design,
quality assurance and control, interpretation, and da

‘/>”/>

SOURCE